References
Query Results -- Details
MGI Accession ID: MGI:3573961
J Number: J:96922
Other Accession IDs:
Title: Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.
Authors: Drake CG; Doody AD; Mihalyo MA; Huang CT; Kelleher E; Ravi S; Hipkiss EL; Flies DB; Kennedy EP; Long M; McGary PW; Coryell L; Nelson WG; Pardoll DM; Adler AJ
Journal: Cancer Cell
Volume: 7
Issue: 3
Date: 2005 Mar
Year: 2005
Pages: 239-49
Review Status: Peer Reviewed
Abstract:
To understand the T cell response to prostate cancer, we created transgenic mice that express a model antigen in a prostate-restricted pattern and crossed these animals to TRAMP mice that develop spontaneous prostate cancer. Adoptive transfer of prostate-specific CD4 T cells shows that, in the absence of prostate cancer, the prostate gland is mostly ignored. Tumorigenesis allows T cell recognition of the prostate gland--but this recognition is tolerogenic, resulting in abortive proliferation and ultimately in hyporesponsiveness at the systemic level. Androgen ablation (the most common treatment for metastatic prostate cancer) was able to mitigate this tolerance--allowing prostate-specific T cells to expand and develop effector function after vaccination. These results suggest that immunotherapy for prostate cancer may be most efficacious when administered after androgen ablation.
Additional Information:
